PUBLIKATIONEN

Originalarbeiten

[39] Hammer, M., Muuss, M., Schickhardt, S., Scheuerle, A., Khoramnia, R., Labuz, G., Uhl, P., Auffarth, G.U. “Forward Light Scattering of the vitreous body after enzymatic aging: An in-vitro model to study vitreous opacification”, Investigative Ophthalmology & Visual Science (2024), accepted manuscript.

[38] Werner, J., Umstätter, F., Hertlein, T., Mühlberg, E., Beijer, B., Wohlfart, S., Zimmermann, S., Haberkorn, U., Ohlsen, K., Fricker, G., Mier, W. & Uhl, P. “Oral delivery of the vancomycin derivative FU002 by a surface-modified liposomal nanocarrier“, Advanced Healthcare Materials (2024), accepted manuscript

[37] Werner, J., Umstätter, F., Hertlein, T., Beijer, B., Kleist, C., Mühlberg, E., Zimmermann, S., Haberkorn, U., Ohlsen, K., Fricker, G., Mier, W., & Uhl, P. “Improved pharmacokinetics and enhanced efficacy of the vancomycin derivative FU002 using a liposomal nanocarrier“, Nanomedicine NBM (2023), accepted manuscript.

[36] Hartl, N., Gabold, B., Uhl, P., Kromer, A., Xiao, X., Mier, W., Liu, R., Merkel, O.A. “ApoE – Functionalization of Nanoparticles for Targeted Brain Delivery – A Feasible Method for Polyplexes?” Drug Delivery and Translational Research (2023), accepted manuscript. PMID: 38087181.

[35] Hammer, M., Britz, L., Schickhardt, S., Lieberwirth, I., Munro, D., Uhl, P., Scheuerle, A., Khoramnia, R., Łabuz, G., Auffarth, G.U. “Quantification of straylight induced by silicone oil adherent to intraocular lenses of different materials.” American Journal of Ophthalmology (2023), accepted manuscript.

[34] Dürr, V., Wohlfart, S., Eisenzapf, T., Mier, W., Fricker, G., Uhl, P. “Oral Delivery of mRNA by Liposomes Functionalized with Cell-Penetrating Peptides”, Applied Nano 4 (2023), 293-308. https://doi.org/10.3390/applnano4040017

[33] Hammer, M., Herth, J., Muuss, M., Schickhardt, S., Scheuerle, A., Khoramnia, R., Labuz, G., Uhl, P., Auffahrt, G.U. “Forward light scattering of first to third generation vitreous body replacement hydrogels after surgical application compared to conventional silicone oils and vitreous body”, Gels, 9 (2023), 837. PMID: 37888410.

[32] Hammer, M., Schickhardt, S., Munro, D., Scheuerle, A., Khoramnia, R., Uhl, P., Auffarth, G.U. “New approaches to explanting high-viscosity silicone oil in retinal surgery – Polyimide cannulas vs extraction sleeves vs a luer-trocar.” International Journal of Retina and Vitreous. 9 (2023), 43. PMID: 37488630.

[31] Hartl, N., Gabold, B., Adams, F., Uhl, P., Oerter, S., Gätzner, S., Metzger, M., König, A.C., Hauck, S.M., Appelt-Menzel, A., Mier, W., Fricker, G., Merkel, O.M. “ Overcoming the Blood-Brain Barrier? Prediction of Blood-Brain Permeability of Hydrophobically Modified Polyethylenimine Polyplexes for siRNA Delivery into the Brain with in vitro and in vivo models.” Journal of Controlled Release. 360 (2023), 613-629. PMID: 37437848.

[30] Uhl, P., Bajraktari-Sylejmani, G., Witzigmann, D., Zimmermann, S., Burhenne, J., Wiess, J., Heafeli, W.E., Sauter, M. “A nanocarrier approach for oral peptide delivery: evaluation of cell-penetrating-peptide modified liposomal formulations in dogs”, Advanced Therapeutics. 2023, 2300021. https://doi.org/10.1002/adtp.202300021.

[29] Uhl, P. “Online statt Präsenz: Umarbeitung des Seminars „Pharmazeutische Toxikologie“ in ein Online-Format anhand des „Scholarship of Teaching“ HINT. Heidelberg Inspirations for Innovative Teaching 3 (2022), 167-186. https://doi.org/10.11588/hint.2022.1.92857

[28] Umstätter, F., Werner, J., Zerlin, L., Mühlberg, E., Kleist, C., Klika, K. D., Hertlein, T., Beijer, B., Domhan, C., Zimmermann, S., Ohlsen, K., Haberkorn, U., Mier, W. & Uhl, P. “Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics.” Pharmaceuticals 15 (2022), 159. PMID: 35215272

[27] Hammer, M., Schickhardt, S. K., Merz, P. R., Khoramnia, R., Scheuerle, A. F., Mier, W., Uhl, P. & Auffarth, G. U. “Intravitreal Application: Physicochemical Properties of Drugs Dissolved in Silicone Oils of Different Density in Comparison to the Porcine Vitreous Body.” Pharmaceutics 14 (2022), 1364. PMID: 35890260.

[26] Benzel, J., Bajraktari-Sylejmani, G., Uhl, P., Davis, A., Nair, S., Pfister, S.M., Haefeli, W.E., Weiss, J., Burhenne, J., Pajtler, K.W. & Sauter, M. “Investigating the Central Nervous System Disposition of Actinomycin D: Implementation and Evaluation of Cerebral Microdialysis and Brain Tissue Measurements Supported by UPLC-MS/MS Quantification.“ Pharmaceutics 13 (2021): 1498. PMID: 34575574

[25] Pratsinis A., Uhl, P., Bolten, J.S., Hauswirth, P., Schenk, S.H., Urban, S., Mier, W., Witzigmann, D. & Huwyler J. “Virus-Derived Peptides for Hepatic Enzyme Delivery.” Molecular Pharmaceutics 18 (2021), 2004-2014. PMID: 33844553

[24] Uhl, P. et al. “Overcoming the Mucosal Barrier: Tetraether Lipid-Stabilized Liposomal Nanocarriers Decorated with Cell-Penetrating Peptides Enable Oral Delivery of Vancomycin” Advanced Therapeutics 4 (2021). https://doi.org/10.1002/adtp.202000247

[23] Storck, P., Umstätter, F., Wohlfart, S., Domhan, C., Kleist, C., Werner, J., Brandenburg, K., Zimmermann, S., Haberkorn, U., Mier, W. & Uhl, P. “Fatty Acid Conjugation Leads to Length-Dependent Antimicrobial Activity of a Synthetic Antibacterial Peptide (Pep19-4LF).“ Antibiotics 9 (2020), 844. PMID: 33255900

[22] Sauter M., Uhl, P., Burhenne J., Haefeli WE. “Application of triple quadrupole tandem mass spectrometry to the bioanalysis of collision-induced dissociation-resistant cyclic peptides − Ultra-sensitive quantification of the somatostatin-analog pasireotide utilizing UHPLC-MS/MS.” Journal of Pharmaceutical and Biomedical Analysis 5 (2020), 113728. PMID: 33234413

[21] Sauter, M., Burhenne, J., Haefeli, W.E. & Uhl, P. “An Underestimated Factor: The Extent of Cross-Reactions Modifying APIs in Surface-Modified Liposomal Preparations Caused by Comprised Activated Lipids.” Molecules 25 (2020), E4436. PMID: 32992540

[20] Mühlberg, E., Umstätter, F., Domhan, C., Hertlein, T., Ohlsen, K., Krause, A., Kleist, C., Beijer, B., Zimmermann, S., Haberkorn, U., Mier, W. & Uhl, P. “Vancomycin-Lipopeptide Conjugates with High Antimicrobial Activity on Vancomycin-Resistant Enterococci.” Pharmaceuticals (Basel). 2020 May 29;13(6):110. PMID: 32485876

[19] Sauter, M., Uhl, P., Burhenne, J. & Haefeli, WE. “Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics.“ Journal of Pharmaceutical and Biomedical Analalysis 15 (2020), 113276. PMID: 32353679

[18] Sauter, M., Uhl, P., Meid, A.D., Mikus, G., Burhenne, J. & Haefeli, WE. “New insights into the pharmacokinetics of vancomycin after oral and intravenous administration: An investigation in beagle dogs.“ Journal of Pharmaceutical Sciences 109 (2020), 2090-2094, PMID: 32201235

[17] Umstätter, F.; Domhan, C., Hertlein, T., Ohlsen, K., Mühlberg, E., Kleist, C., Zimmermann, S., Beijer, B., Klika, K.D., Haberkorn, U., Mier, W. & Uhl, P. “Inside Back Cover: Vancomycin Resistance Is Overcome by Conjugation of Polycationic Peptides (Angewandte Chemie Internationale Edition 23/2020).“ https://doi.org/10.1002/anie.202004925

[16] Umstätter, F.; Domhan, C., Hertlein, T., Ohlsen, K., Mühlberg, E., Kleist, C., Zimmermann, S., Beijer, B., Klika, K.D., Haberkorn, U., Mier, W. & Uhl, P. “Überwindung von Vancomycinresistenzen durch Modifikation mit polykationischen Peptiden.“ Angewandte Chemie 2020. https://doi.org/10.1002/ange.202002727

[15] Umstätter, F.; Domhan, C., Hertlein, T., Ohlsen, K., Mühlberg, E., Kleist, C., Zimmermann, S., Beijer, B., Klika, K.D., Haberkorn, U., Mier, W. & Uhl, P. “Vancomycin Resistance is Overcome by Conjugation of Polycationic Peptides.“ Angewandte Chemie Internationale Edition 59 (2020), 8823-8827. PMID: 32190958

[14] Sauter, M., Uhl, P., Burhenne, J. & Haefeli, WE. “Post-extraction disulfide bond cleavage for MS/MS quantification of collision-induced dissociation-resistant cystine-cyclized peptides and its application to the ultra-sensitive UPLC-MS/MS bioanalysis of octreotide in plasma.” Analytica Chimica Acta 1114 (2020), 42-49. PMID: 32359513

[13] Schuster, L., Sauter, M., Uhl, P., Meid, A., Haefeli, W.E., Weiss, J. & Theile, D. “Reporter cell assay-based functional quantification of TNF-α-antagonists in serum — a proof-of-principle study for adalimumab.”  Analytical Biochemistry 596 (2020), 113646., PMID: 32112722

[12] Sauter, M., Uhl, P., Haefeli, WE. & Burhenne, J. “Ultra-sensitive bioanalysis of the therapeutic peptide exenatide for accurate pharmacokinetic analysis at effective plasma concentrations utilizing UPLC-MS/MS.” Journal of Pharmaceutical Analysis 10 (2020), 233-239. PMID: 32612869

[11] Uhl, P. et al. “Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide.” Nanomedicine: Nanotechnology, Biology and Medicine Nanomedicine. 2020:102132. PMID: 31783138

[10] Domhan, C., Uhl, P., Kleist, C., Zimmermann, S., Umstätter, F., Leotta, K., Mier, W. & Wink, M. “Replacement of l-Amino Acids by d-Amino Acids in the Antimicrobial Peptide Ranalexin and Its Consequences for Antimicrobial Activity and Biodistribution.” Molecules 24 (2019), E2987. PMID: 31426494

[9] Witzigmann, D., Uh, P., Sieber, S., Kaufman, C., Einfalt, T., Schöneweis, K., Grossen, P., Buck, J., Ni, Y., Schenk, S.H., Hussner, J., Meyer zu Schwabedissen, H.E., Quebatte, G., Mier, W., Urban, S. & Huwyler, J. “Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide.” Elife 2019, e42276. PMID: 31333191

[8] Sauter M., Uhl, P., Foerster, K.I., Mohr, I., Höne, R.T. Merle, U. Burhenne, J. & Haefeli WE. “An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasma.” Journal of Pharmaceutical and Biomedical Analysis, 174 (2019), 633-638. PMID: 31279892

[7] Sauter, M., Uhl, P. , Majewsky, M., Fresnais, M., Haefeli, W.E. & Burhenne, J. “An ultrasensitive UPLC–MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs.” Bioanalysis 11 (2019), 887-898. PMID: 31094209

[6] Sieber, S., Grossen, P., Uhl, P. , Detampel. P., Mier, W., Witzigmann, D. & Huwyler, J. “Zebrafish as a predictive screening model to assess macrophage clearance of liposomes in vivo.” Nanomedicine: Nanotechnology, Biology and Medicine 17 (2019), 82-93. PMID: 30659929

[5] Kruse, S., Büchler, M., Uhl, P., Sauter, M., Scherer, P., Lan, T.C.T., Zottnick, S., Klevenz, A., Yang, R., Rösl, F., Mier, W. & Riemer, AB. “Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model.” OncoImmunology, 8 (2018), e1524694. PMID: 30546964

[4] Domhan, C., Uhl, P., Meinhardt, A., Zimmermann, S., Kleist, C., Lindner, T., Leotta, K., Mier, W. & Wink, M. “A novel tool against multiresistant bacterial pathogens–lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics.” International Journal of Antimicrobial Agents 52 (2018), 52-62. PMID: 29649587

[3] Uhl, P. et al. “Oral delivery of vancomycin by tetraether lipid liposomes.“ European Journal of Pharmaceutical Sciences 108 (2017), 111-118. PMID: 28716758

[2] Tremmel, R., Uhl, P. , Helm, F., Wupperfeld, D:, Sauter, M., Mier, W., Stremmel, W., Hofhaus, G. & Fricker, G. “Delivery of Copper-chelating Trientine (TETA) to the central nervous system by surface modified liposomes.“ International Journal of Pharmaceutics, 512 (2016), 87-95. PMID: 27553779

[1] Uhl, P. et al. “A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B.“ European Journal of Pharmaceutics and Biopharmaceutics 103 (2016), 159-166. PMID: 27049970

Übersichtsartikel

[9] Pander, G., Uhl, P., Kühl, N., Haberkorn, U., Anderl, J. & Mier, W. “Antibody–drug conjugates: what drives their progress?” Drug Discovery Today 27 (2022), 103311. PMID: 35787480

[8] Mühlberg E., Burtscher, M., Umstätter, F., Fricker, G., Mier, W. & Uhl, P. “Trends in liposomal nanocarrier strategies for the oral delivery of biologics.”, Nanomedicine 16 (2021), 1813-1832. PMID: 34269068

[7] Uhl, P., Umstätter, F., Domhan, C., Hertlein, T., Ohlsen, K., Zimmermann, S. & Mier, W. “Bakterielle Resistenzen überwinden – Reaktivierung etablierter Antibiotika mittels Peptidkonjugation” Wiley Analytical Sciences 2021. https://analyticalscience.wiley.com/do/10.1002/was.000600074/full/

[6] Uhl, P. et al. “Eine Strategie zur Überwindung von Vancomycin-Resistenzen.” Pharmakon 4/2020.

[5] Mühlberg, E., Umstätter, F., Kleist, C., Domhan, C., Mier, W. & Uhl, P. “Renaissance of Vancomycin: Approaches for Breaking Antibiotic-Resistance in Multidrug-Resistant Bacteria.” Canadian Journal of Microbiology 66 (2020), 11-16. PMID: 31545906

[4] Uhl, P. “Schnell oder langsam – wie sich die Freisetzung von Arzneistoffen modifizierten lässt.” Deutsche Apotheker Zeitung 28 (2019), p. 48f, 11.07.2019

[3] Uhl, P., Haberkorn, U., & Mier, W. “Frühe Diagnosen durch PET.” Deutsche Apotheker Zeitung 29 (2015) p. 50f, 16.07.2015

[2] Uhl, P., Fricker, G., Haberkorn, U. & Mier, W. “Radionuclides in drug development.“ Drug Discovery Today 20 (2015), 198-208. PMID: 25304182

[1] Uhl, P., Fricker, G., Haberkorn, U. & Mier, W. “Current status in the therapy of liver diseases.“ International Journal of Molecular Sciences 15 (2014), 7500-7512. PMID: 24786290

Patente

[7] “Oral pharmaceutical compositions comprising lipid conjugates” (PCT/EP2021/069648)
[6] “Method of making oral dosage forms“ (EP3628309A1)
[5] “Improved polypeptide coupled antibiotics“ (EP19769720.4)
[4] “Liposomal compositions and solid dosage forms comprising the same“ (WO/2018/178395)
[3] “Coating of nanoparticle surfaces with cyclopeptides for improving delivery of agents“ (WO2018065085A1)
[2] “Liposomes containing cell penetrating peptides and tetraether lipids for the oral delivery of macromolecules“ (WO/2017/067642)
[1] “Novel liposomal formulation for the oral hepatic delivery of drugs“ (WO2017067640A1)